BusinessLB-100 and LB-102, Lixte Biotechnology’s Protein Phosphatase 2A Inhibitors, Sensitize BCR-ABL Leukemia Stem Cells to Targeted Therapy with Tyrosine Kinase InhibitorsBy Nasdaq OMXFeb 9, 2018, 2:45 PM UTC
BusinessPROVECTUS ANNOUNCES RESULTS FROM ELICITATION STUDY OF PATIENT-PERCEIVED IMPACTS FROM STAGE III AND EARLY-STAGE IV MELANOMABy Nasdaq OMXOct 23, 2017, 12:00 PM UTC
BusinessNeoTherma Oncology Announces FDA Granted Its Vectron Thermal Device for Treatment of Pancreatic Cancer Breakthrough Device Designation within Expedited Access PathwayBy Nasdaq OMXApr 4, 2017, 2:06 PM UTC
BusinessMidatech Pharma PLC (“Midatech” or the “Company”) Audited financial results for the year ended 31 December 2015By Nasdaq OMXApr 13, 2016, 6:00 AM UTC
BusinessMidatech’s Commercial Launch of Zuplenz® (Ondansetron) Oral Soluble Film to Prevent Post-Operative, Chemotherapy and Radiation-Induced Nausea and Vomiting in USBy Nasdaq OMXApr 11, 2016, 6:00 AM UTC
